Bahrain has made a groundbreaking move by becoming the first country in the Middle East and the second country worldwide to approve the use of CASGEVY (exagamglogene autotemcel) for the treatment of patients with sickle cell disease and transfusion-dependent beta-thalassemia. Developed by Vertex Pharmaceuticals and CRISPR Therapeutics, this treatment has undergone successful clinical trials in several countries, including the UK, US, France, Italy, and Germany. This approval signifies Bahrain’s commitment to pioneering healthcare solutions and providing a better quality of life for individuals suffering from these blood disorders.
CASGEVY utilizes CRISPR, a cutting-edge gene-editing technique, to treat a wide range of genetic disorders. By utilizing CRISPR, scientists can use edited stem cells from patients to generate fully functioning hemoglobin, offering hope for previously untreatable conditions such as sickle cell anemia. By embracing this revolutionary therapy, Bahrain not only demonstrates its dedication to improving the health and well-being of its people but also positions itself at the forefront of medical advancements in the region.
The approval by the National Health Regulatory Authority (NHRA) of the Kingdom of Bahrain follows thorough analysis and review. Currently, sickle-cell patients in Bahrain have limited global treatment options, with bone marrow transplants being one of the only available cures. CASGEVY provides a new cluster of treatments for Bahrainis, and its approval showcases the country’s visionary leadership, innovation, and commitment to enhancing the lives of its citizens through high-quality healthcare and well-being.
